Bringing Cell and Gene Therapies to Market, Faster

With recent approvals in a variety of different cell and gene therapies (CAGTs), we are progressing toward a new day for patients. But development poses unprecedented challenges for sponsors. Pipelines are increasingly constricted due to financial pressures. Making choices about which assets will go forward and how to develop them will be fundamental to our industry’s success — and successful partnerships are needed to create advantages now and in the years ahead. In this report, Parexel experts share insights to help bring these complex treatments to market faster and more efficiently.